© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
August 24, 2022
Matthew J. Frigault, MD, discussed safety and efficacy findings on CART-ddBCMA.
August 23, 2022
At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.
April 29, 2022
Several CAR T-cell therapies have proved to be efficacious in hematological malignancies; however, developing a safe and effective CAR T-cell approach for solid tumors has remained a challenge.
March 07, 2022
Oliver Van Oekelen, MD, MSc, resident and PhD student, Icahn School of Medicine, Mount Sinai, discussed findings from a retrospective study.
August 07, 2021
Jan Philipp Bewersdorf, MD, hospital resident at Yale University School of Medicine discussed the safety and efficacy of allogeneic hematopoietic stem cell transplant in myelofibrosis.
July 28, 2021
Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.